Report Scope:
The scope of this study encompasses an investigation of cell and gene therapy tools: GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. The key player analyzes each tool type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next six years. The current report provides detailed analysis of the market’s drivers, challenges and opportunities. The report also covers market projections to 2027 and market share for key market players. The report includes the company profiles of key players with detailed information about business segments, financials, product portfolios and recent developments. The report provides impact analysis of the COVID-19 pandemic on this market.

Report Includes:

  • 105 total tables
  • An updated overview of the global market for immunoassay-based cell and gene therapy tools and reagents
  • Analyses of the global market trends, with historic market revenue for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the market potential for the cell and gene therapy tools and reagents in the life sciences industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of actual market size and revenue forecast for cell and gene therapy tools and reagents in USD million terms, and corresponding market share analysis based on product, application/disease area, end-user, and region
  • In-depth information (facts and figures) concerning major market dynamics (DROs), product innovations, clinical trials, and various government regulations affecting the market outlook for cell and gene therapy tools and reagents
  • Review of prevalence of infectious disease, metabolic disorders and chronic ailments; along with the recent technological advancements, competitive environment, and the industry value chain analysis
  • Coverage of the technological, economic, and business considerations of the prevailing cell and gene therapy tools market, and its vendor landscape
  • Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology
  • Identification of the companies best positioned to meet the demand for cell and gene therapy in life sciences applications owing to their proprietary technologies, novel product launches, key mergers and acquisition deals, and other strategic advantages
  • Descriptive company profiles of the market leading players, including Abcam, Akron Biotech, Adverum Biotechnologies and Avrobio.